Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 54 EUR -1.1% Market Closed
Market Cap: 522.7m EUR
Have any thoughts about
Pharmanutra SpA?
Write Note

Pharmanutra SpA
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharmanutra SpA
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Pharmanutra SpA
MIL:PHN
Current Portion of Long-Term Debt
€4.2m
CAGR 3-Years
63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intercos SpA
MIL:ICOS
Current Portion of Long-Term Debt
€7.9m
CAGR 3-Years
-60%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Bioera SpA
MIL:BIE
Current Portion of Long-Term Debt
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Enervit SpA
MIL:ENV
Current Portion of Long-Term Debt
€4.3m
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Pharmanutra SpA
Glance View

Market Cap
518.8m EUR
Industry
Consumer products

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

PHN Intrinsic Value
42.67 EUR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Pharmanutra SpA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
4.2m EUR

Based on the financial report for Sep 30, 2024, Pharmanutra SpA's Current Portion of Long-Term Debt amounts to 4.2m EUR.

What is Pharmanutra SpA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
63%

Over the last year, the Current Portion of Long-Term Debt growth was 8%. The average annual Current Portion of Long-Term Debt growth rates for Pharmanutra SpA have been 63% over the past three years .

Back to Top